Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these comapnies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

#1 - Clene

NASDAQ:CLNN
Stock Price: $0.30 (+$0.02)
PE Ratio: -0.64
Market Cap: $38.09 million
Average Trading Volume: 1.35 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.80 (2,529.8% Upside)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

#2 - Gamida Cell

NASDAQ:GMDA
Stock Price: $0.41 (+$0.01)
PE Ratio: -1.38
Market Cap: $43.58 million
Average Trading Volume: 2.42 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.40 (1,208.5% Upside)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

#3 - Jasper Therapeutics

NASDAQ:JSPR
Stock Price: $0.79 (+$0.07)
PE Ratio: -0.95
Market Cap: $88.03 million
Average Trading Volume: 1.31 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.96 (655.7% Upside)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

#4 - Unicycive Therapeutics

NASDAQ:UNCY
Stock Price: $0.87 (-$0.01)
PE Ratio: -0.50
Market Cap: $30.16 million
Average Trading Volume: 204,104 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.88 (922.8% Upside)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

#5 - Affimed

NASDAQ:AFMD
Stock Price: $0.63 (+$0.09)
PE Ratio: -0.74
Market Cap: $93.34 million
Average Trading Volume: 1.58 million shares
Consensus Rating: Moderate Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.33 (753.3% Upside)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

#6 - Village Farms International

NASDAQ:VFF
Stock Price: $0.76 (-$0.04)
PE Ratio: -1.23
Market Cap: $83.89 million
Average Trading Volume: 452,306 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.73 (258.1% Upside)

Village Farms International, Inc., together with its subsidiaries, produces, markets, and sells greenhouse-grown tomatoes, bell peppers, and cucumbers in North America. It operates through four segments: Produce, Cannabis-Canada, Cannabis-U.S., and Energy. The company also owns and operates a power plant that generates and sells electricity, and provides thermal heat to British Columbia Hydro and Power Authority; produces and supplies cannabis products to other licensed providers and provincial governments in Canada and internationally; and develops and sells cannabinoid-based health and wellness products, including ingestible, edibles, and topical applications. It markets and distributes its products under the Village Farms brand name to retail supermarkets and fresh food distribution companies, as well as products produced under exclusive arrangements with other greenhouse producers. The company was formerly known as Village Farms Canada Inc. and changed its name to Village Farms International, Inc. in December 2009. Village Farms International, Inc. was founded in 1989 and is headquartered in Delta, Canada.

#7 - X4 Pharmaceuticals

NASDAQ:XFOR
Stock Price: $0.84 (-$0.03)
PE Ratio: -1.06
Market Cap: $140.27 million
Average Trading Volume: 3.56 million shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.20 (281.6% Upside)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

#8 - FTC Solar

NASDAQ:FTCI
Stock Price: $0.69 (-$0.02)
PE Ratio: -1.28
Market Cap: $86.60 million
Average Trading Volume: 1.35 million shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.17 (212.7% Upside)

FTC Solar, Inc. provides solar tracker systems, software, and engineering services in the United States and internationally. It offers two-panel in-portrait single-axis tracker solutions under the Voyager brand name. The company also provides Pioneer, a one module-in-portrait solar tracker solution that allows for a pile count reduction per megawatt. Its customers include project developers; solar asset owners; and engineering, procurement, and construction contractors that design and build solar energy projects. FTC Solar, Inc. was incorporated in 2017 and is headquartered in Austin, Texas.

#9 - Aeva Technologies

NYSE:AEVA
Stock Price: $0.76 (-$0.07)
PE Ratio: -1.13
Market Cap: $169.31 million
Average Trading Volume: 1.14 million shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $1.62 (113.1% Upside)

Aeva Technologies, Inc. designs 4D LiDAR-on-chips in the United States, Thailand, Europe, the Middle East, and Asia. The company develops its products using frequency modulated continuous wave sensing technology. It offers 4D LiDAR sensing system with embedded software for automotive, industrial, and security applications; and a silicon photonics engine and software algorithms for industrial automation and consumer device applications. The company was founded in 2017 and is based in Mountain View, California.

#10 - Coppernico Metals

OTCMKTS:CPPMF
Stock Price: $0.02
PE Ratio: 0.17
Market Cap: $3.22 million
Average Trading Volume: 76,796 shares
P/E Ratio: 0.2
Consensus Rating: Moderate Buy (3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.38 (29,066.7% Upside)

Copper Mountain Mining Corporation engages in the mining, exploration, and development of mineral properties in Canada. It explores for copper, gold, and silver deposits. The company holds 75% interests in the Copper Mountain mine comprising 135 crown-granted mineral claims, 145 located mineral claims, 14 mining leases, 12 fee simple properties, and seven cell claims that covers an area of approximately 6,354 hectares located to the south of Princeton, British Columbia. Copper Mountain Mining Corporation was incorporated in 2006 and is headquartered in Vancouver, Canada. As of June 20, 2023, Copper Mountain Mining Corporation operates as a subsidiary of Hudbay Minerals Inc.

#11 - Chicken Soup for the Soul Entertainment

NASDAQ:CSSE
Stock Price: $0.22
PE Ratio: -0.01
Market Cap: $7.07 million
Average Trading Volume: 328,811 shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.60 (1,996.6% Upside)

Chicken Soup for the Soul Entertainment, Inc. operates as a streaming video-on-demand (VOD) company in the United States and internationally. It owns and operates various ad-supported and subscription-based VOD networks, including Crackle, Chicken Soup for the Soul, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Popcornflix Comedy, Españolflix, and FrightPix. The company distributes and exhibits content through the Crackle Plus and Redbox streaming services including AVOD, FAST, TVOD platforms, such as connected TVs, smartphones, tablets, gaming consoles, and the web through its owned and operated platforms. It also produces and licenses movies, television series, and programs; and produces long and short-form video content. Chicken Soup for the Soul Entertainment, Inc. was founded in 2014 and is headquartered in Cos Cob, Connecticut. Chicken Soup for the Soul Entertainment, Inc. operates as a subsidiary of Chicken Soup for the Soul Productions, LLC.

#12 - Rent the Runway

NASDAQ:RENT
Stock Price: $0.53 (-$0.06)
PE Ratio: -0.31
Market Cap: $37.10 million
Average Trading Volume: 1.18 million shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $2.86 (441.6% Upside)

Rent the Runway, Inc. operates shared designer closet in the United States. The company offers evening wear and accessories, ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear under subscription, rental, and resale offering. It also engages in the software development and support activities. The company was incorporated in 2009 and is headquartered in Brooklyn, New York.

#13 - Cara Therapeutics

NASDAQ:CARA
Stock Price: $0.74 (-$0.02)
PE Ratio: -0.35
Market Cap: $40.48 million
Average Trading Volume: 1.22 million shares
Consensus Rating: Moderate Buy (4 Buy Ratings, 1 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $12.93 (1,640.0% Upside)

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

#14 - Karyopharm Therapeutics

NASDAQ:KPTI
Stock Price: $0.87 (-$0.06)
PE Ratio: -0.66
Market Cap: $99.07 million
Average Trading Volume: 1.45 million shares
Consensus Rating: Moderate Buy (3 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.86 (577.1% Upside)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

#15 - Galecto

NASDAQ:GLTO
Stock Price: $0.72 (-$0.06)
PE Ratio: -0.41
Market Cap: $19.52 million
Average Trading Volume: 651,237 shares
Consensus Rating: Hold (3 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.60 (955.6% Upside)

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled small molecule inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

#16 - Outlook Therapeutics

NASDAQ:OTLK
Stock Price: $0.39 (-$0.03)
PE Ratio: -1.64
Market Cap: $102.54 million
Average Trading Volume: 1.70 million shares
Consensus Rating: Hold (3 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.17 (957.5% Upside)

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

#17 - Oncternal Therapeutics

NASDAQ:ONCT
Stock Price: $0.54 (+$0.05)
PE Ratio: -0.74
Market Cap: $31.62 million
Average Trading Volume: 475,753 shares
Consensus Rating: Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.58 (566.7% Upside)

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

#18 - NanoString Technologies

NASDAQ:NSTG
Stock Price: $0.75 (-$0.05)
PE Ratio: -0.21
Market Cap: $36.01 million
Average Trading Volume: 1.36 million shares
Consensus Rating: Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.63 (918.8% Upside)

NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.

#19 - Gossamer Bio

NASDAQ:GOSS
Stock Price: $0.91 (+$0.03)
PE Ratio: -0.52
Market Cap: $205.69 million
Average Trading Volume: 2.07 million shares
Consensus Rating: Hold (2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.75 (311.0% Upside)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

#20 - Americas Silver

NYSEAMERICAN:USAS
Stock Price: $0.25
PE Ratio: -1.41
Market Cap: $55.55 million
Average Trading Volume: 680,395 shares
Consensus Rating: Hold (2 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $2.30 (805.5% Upside)

Americas Gold and Silver Corporation engages in the acquisition, evaluation, exploration, development, and operation of mineral properties. The company explores for silver, lead, zinc and copper. It principally owns 100% interests in the Cosalá Operations consisting of 67 mining concessions that cover approximately 19,385 hectares located in the state of Sinaloa, Mexico; and Galena Complex situated near the town of Wallace in the state of Idaho, the United States. The company was formerly known as Americas Silver Corporation and changed its name to Americas Gold and Silver Corporation in September 2019. Americas Gold and Silver Corporation was incorporated in 1998 and is headquartered in Toronto, Canada.

#21 - Li-Cycle

NYSE:LICY
Stock Price: $0.58 (-$0.07)
Market Cap: $104.16 million
Average Trading Volume: 4.83 million shares
Consensus Rating: Hold (4 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $7.00 (1,097.0% Upside)

Li-Cycle Holdings Corp. engages in the lithium-ion battery resource recovery and lithium-ion battery recycling business in North America. The company offers a mix of cathode and anode battery materials, including lithium, nickel, and cobalt, as well as graphite, copper, and aluminum; and copper and aluminum metals. It also provides hub products, such as lithium carbonate, cobalt sulphate, nickel sulphate, and manganese carbonate. The company is headquartered in Toronto, Canada.

#22 - The Restaurant Group

OTCMKTS:RSTGF
Stock Price: $0.56
Consensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $70.00 (12,397.8% Upside)

The Restaurant Group plc operates restaurants and pubs in the United Kingdom. Its brands include Wagamama, Frankie & Benny's, Brunning & Price, Chiquito, Coast to Coast, Firejacks, and Barburrito. The company also operates TRG concessions that provide table and counter services, as well as sandwich shops, pubs, and bars. In addition, it engages in the franchise operations primarily in Europe and the Middle East. The company was incorporated in 1954 and is headquartered in London, the United Kingdom.

#23 - SVB Financial Group

OTCMKTS:SIVPQ
Stock Price: $0.18 (-$0.02)
PE Ratio: 0.01
Market Cap: $10.66 million
Average Trading Volume: 92,996 shares
P/E Ratio: 0.0
Consensus Rating: Hold (4 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $284.44 (157,924.7% Upside)

SVB Financial Group, a diversified financial services company, offers various banking and financial products and services. It operates through four segments: Silicon Valley Bank, SVB Private, SVB Capital, and SVB Securities. The Silicon Valley Bank segment provides commercial banking products and services, including credit, treasury management, foreign exchange, trade finance, and other financial products and services. This segment also offers traditional term, growth capital term, and equipment loans, asset-based loans, revolving lines of credit, warehouse facilities, recurring revenue and acquisition finance facilities, mezzanine lending, corporate working capital facilities, and credit card programs; treasury management products and services; business and analysis checking, money market, multi-currency, in-country bank, and sweep accounts; receivables services, which include merchant services, remote capture, lockbox, and fraud control services; wire transfer and automated clearing house payment services; business bill pay, credit and debit cards, account analysis, and disbursement services. In addition, it offers foreign exchange and trade finance products and services; letters of credit; and investment services and solutions. The SVB Private segment offers mortgages, home equity lines of credit, restricted and private stock loans, capital call lines of credit, and other secured and unsecured lending products; planning-based financial strategies, wealth management, family office, financial planning, tax planning, and trust services; and real estate secured loans. The SVB Capital segment provides venture capital investment services. The SVB Securities segment provides investment banking services; products and services, including capital raising, merger and acquisition advisory, equity research, and sales and trading. The company was founded in 1983 and is headquartered in Santa Clara, California. On March 17, 2023, SVB Financial Group, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

#24 - Nel ASA

OTCMKTS:NLLSF
Stock Price: $0.68
Average Trading Volume: 36,719 shares
Consensus Rating: Hold (3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: N/A

Nel ASA, a hydrogen company, provides various solutions to produce, store, and distribute hydrogen from renewable energy in Norway and internationally. The company operates in two segments, Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment produces H2Station hydrogen fueling stations that provide fuel cell electric vehicles with the fueling and long range as conventional fossil fuel vehicles, include cars, buses, trucks, and other applications. The Nel Hydrogen Electrolyser segment supplies hydrogen production equipment based on alkaline and proton exchange membrane water electrolysis technology. It serves industry, energy, and gas companies. The company was formerly known as DiaGenic ASA and changed its name to Nel ASA in October 2014. Nel ASA was founded in 1927 and is headquartered in Oslo, Norway.

#25 - Sangamo Therapeutics

NASDAQ:SGMO
Stock Price: $0.54 (-$0.06)
PE Ratio: -0.37
Market Cap: $96.35 million
Average Trading Volume: 1.42 million shares
Consensus Rating: Hold (3 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target: $4.68 (760.5% Upside)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

More Stock Ideas from MarketBeat

Stock Lists:

Cheap Stocks:

Stocks By Exchange:

Latest Stock Ideas:

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial